The management of multiple myeloma (MM) has evolved rapidly over the past decade, due in large part to the addition of thalidomide, lenalidomide, and bortezomib to the treatment paradigm for the disease. Myeloma is currently staged using the International Staging System (ISS), which utilizes 2 laboratory parameters (paraproteins and albumin) to determine prognosis.1 According to this staging system, the median survival times for patients with stage I, II, and III disease are 62, 44, and 29 months, respectively.
The clinical entity of multiple myeloma (MM) exhibits great heterogeneity. Some patients present with advanced, bulky, or rapidly evolving disease, whereas others have indolent, asymptomatic disease (eg, smoldering multiple myeloma) and require no treatment for a considerable period of time.1,2 At the time of diagnosis, clinicians must first identify which patients need immediate treatment, and then tailor management strategies based on several factors that influence post-treatment outcomes.
Results 1 - 5 of 5